Cite
Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis.
MLA
Quiros, Jorge R., et al. “Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-Analysis.” Infection & Chemotherapy, vol. 53, no. 3, Sept. 2021, pp. 436–48. EBSCOhost, https://doi.org/10.3947/ic.2020.0126.
APA
Quiros, J. R., Ross-Comptis, J., Hathaway III, D., Sarfraz, A., Sarfraz, Z., Grigoryan, Z., Romero, K. A., Gapizov, A., Príncipe-Meneses, F. S., Somagutta, M. R., Riva-Moscoso, A., & Kapasi, A. (2021). Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis. Infection & Chemotherapy, 53(3), 436–448. https://doi.org/10.3947/ic.2020.0126
Chicago
Quiros, Jorge R., Jennifer Ross-Comptis, Donald Hathaway III, Azza Sarfraz, Zouina Sarfraz, Zhanna Grigoryan, Kimberly Anne Romero, et al. 2021. “Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-Analysis.” Infection & Chemotherapy 53 (3): 436–48. doi:10.3947/ic.2020.0126.